Sanofi reported net cash proceeds of about 10 billion ($10.7 billion) from the deal, which it had outlined earlier in 2024.

Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

AFRY Management Consulting has released a report titled Factors for the Siting of Biorefineries for the CSA Group, providing crucial insights int ...